Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.
Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting promising response rates but significant toxicity concerns that currently limit widespread adoption to select high-risk patients, pending further trial data and safety protocol development.
The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.
Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.
Khurshid R. Ghani, MBChB, MS, FRCS, discusses how results from the SOUL trial may shape clinical decision-making regarding stent placement.
“Our findings support that that we do not drop the label of cancer from grade group 1 nomenclature," says Jim C. Hu, MD, MPH.
A significant challenge lies in differentiating prostate cancer symptoms from common age-related issues.
Howard B. Goldman, MD, discusses the rationale and development process for the Glean Urodynamics System.
A panelist discusses how adherence considerations are crucial when selecting between different abiraterone formulations, emphasizing that the microformulation offers flexibility by allowing administration with or without food compared with the traditional fasting requirements.
A panelist discusses how a man aged 74 years with mCRPC who progressed on enzalutamide was successfully treated with abiraterone, highlighting the importance of selecting the appropriate formulation based on patient adherence and lifestyle factors.
Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
Murilo De Almeida Luz, MD, discusses data on PSA and ALP changes in patients receiving enzalutamide plus radium-223 vs enzalutamide alone.
Enhancing minority enrollment in clinical trials and utilizing real-world data improves drug safety and efficacy for mHSPC treatments.
Panelists discuss how new molecular imaging technology offers potential to better risk stratify patients eligible for adjuvant pembrolizumab after surgery, potentially identifying those who have undetected metastatic disease requiring more aggressive treatment.
Panelists discuss how the ZIRCON trial results showed impressive test characteristics with 95% positive predictive value for clear cell renal cell carcinoma, meaning a positive test strongly indicates cancer requiring treatment.
Enhancing diversity in mHSPC clinical trials requires community outreach, collaboration, and accessible care for underrepresented populations.
MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54.
A primary concern was establishing trust in the connectivity to ensure no loss in visualization or connection.
"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD.
Panelists discuss current FDA-approved treatments for BCG-unresponsive carcinoma in situ, noting varying response rates among pembrolizumab, nadofaragene, and BCG combined with IL-15 superagonist, while highlighting promising investigational combination immunotherapies like oncolytic viruses and checkpoint inhibitors that may improve outcomes in this challenging patient population.
Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in oncologic outcomes and quality of life, and emphasizing the need for shared decision-making as prospective studies like CISTO refine patient selection for personalized treatment strategies.
One key approach is to increase the representation of women on editorial boards of journals and as reviewers.
Karyn S. Eilber, MD,'s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA
The combination of zanzalintinib plus nivolumab demonstrated encouraging preliminary activity with manageable safety.
Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone.
"My goal [for] a lot of the advocacy that I do is that one day [patients] don't have to do our jobs for us," says Maria Uloko, MD.
“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” says Dean Elterman, MD, MSc.
